Mr. John Armstrong:

Senator Crown is no longer here but he did ask about the drug Ipilimumab. We did quite a detailed process where we work with the National Centre for Pharmacoeconomics to review the effectiveness of any particular new drug. We went through a health technology assessment for that drug to which Senator Crown referred. The advice from the National Centre for Pharmacoeconomics was that it did not meet the cost-effectiveness criteria. We have quite a robust process in place for that.